Thread by @RajlabN

Tracking #SARSCoV2 #Lineages - Globally

Top lineages -#20DayTrends (#G20):

XBB.1.5 (46.4%)⬇️
XBB.1.9.1 (10.1%)⬆️
XBB.1.16 (4.9%)⬆️
EG.1 (3.7%)⬆️
CH.1.1 (2.3%)⬇️
XBB.1.9.2 (2.3%)
--
XBB.2.3 (1.3%)⬆️

Tracker: public.tableau.com/app/profile/ra…

Updated 04/15/23

Granular details #Global #20DayTrends

This analysis includes all designated #SARSCoV2 sequences submitted to @GISAID with sample collection dates on or after 03/26/2023 (15,505 sequences)

#USA, #Austria, #UnitedKingdom & #Canada have submitted a lion's share of sequences with sample collection dates on or after 03/26/2023 ...followed by #Germany, #France, #India, #Italy, #Australia, #Sweden, #Denmark, #Singapore, #SouthKorea, #Spain, #Netherlands

In Silico Immune escape and ACE2 receptor binding scores (relative to BA.2)*

Data is intended to prioritize select lineages to generate rapid laboratory experiments to gauge immune escape and ACE2 binding affinity.

[Credits in the legend] * Only Spike RBD mutations considered

#SARSCoV2 lineages in the zone of concern (red box) - Predicted to have high immune escape and tight ACE2 binding activity - A Closer look

Chart: public.tableau.com/app/profile/ra…

What to expect in the next few weeks?

github.com/neherlab/SARS-…

Excellent SARSCoV2 Variant report

H/T

@richardneher @CorneliusRoemer

“Currently, XBB.1.16 is the big dog” ... “It’s picking up mutations that are common in other variants that will increase its advantage further.”

H/T @ErinMPrater @WellatFortune
@FortuneMagazine fortune.com/well/2023/03/3…